Connect your AI

Schrodinger SDGR Accrued liabilities

Accrued liabilities at other companies

Recursion Pharmaceuticals, Inc.RXRX

——

Other financials

Income statement

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

Market cap$1.15B-41.8%

Enterprise value$984.71M-44.4%

P/S4.5×-4.0×

Profitability

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Schrodinger's accrued liabilities?: Schrodinger (SDGR) reported accrued liabilities of $4.48M in Q1 2026.
How has Schrodinger's accrued liabilities changed year-over-year?: Schrodinger's accrued liabilities increased by 2064.9% year-over-year, from -$228K to $4.48M.